Company intelligence / Profile preview

Cytovia Oncology

Aventura, Florida, United States

Ownership: Private
Employees: ~38
Development stage: Other

Overview

All programs are in preclinical development; recent presentations indicated strong preclinical efficacy of TALEN-edited iNK cells, bispecific antibodies against CD38 and GPC3, and ongoing data in solid and hematologic cancers

Therapeutic areas: Oncology
Modalities: NK cell therapyCAR-NK cell therapyAntibodyBispecific monoclonal antibodyCell and gene therapy
Industry: Biotech

Partnerships

National Cancer Institute (NCI)University of California San Francisco (UCSF)New York Stem Cell Foundation (NYSCF)INSERM/Paris Saint-Louis HospitalCytoImmune Therapeutics

Beyond the preview

Go deeper on Cytovia Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytovia Oncology.

Explore the full profile